AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Drugdiscoverynews

Published November 13, 2026 · Updated November 14, 2026

Another OX40 therapy drops out of the race | Drug Discovery News

Read the full story at Drugdiscoverynews

Psychedelic therapy updates, a novel application for bone marrow, and a hefty price tag for a priority review voucher led the news this week.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics
Psychedelic press release